首页> 美国卫生研究院文献>Cancers >Commercialized Blood- Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis
【2h】

Commercialized Blood- Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis

机译:用于前列腺癌诊断和预后的商业化血液泌尿和组织基生物标志物试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In prostate cancer diagnosis and prognosis, clinicians often must take decisions on which prostate cancer-suspected patients should undergo biopsy and which prostate cancer-diagnosed patients should undergo treatment, to overcome overdiagnosis and overtreatment. Many biomarker-based tests have been developed and commercialized in order to guide decision-making processes of clinicians. Since a variety of biomarker-based tests are currently available, this review provides an overview of all commercially available tests for prostate cancer diagnosis and prognosis. For the diagnostic setting, the PHI, 4K, MiPS, SelectMDx, ExoDx, Proclarix, ConfirmMDx, PCA3 and PCMT are discussed, while for the prognostic setting, the Prolaris, OncotypeDx and Decipher test are discussed. Following, an overview is provided of the studies available comparing the performance of biomarker tests. Next, the use of biomarker tests complementary to the use of multiparametric magnetic resonance imaging in diagnosis of prostate cancer is discussed, which is an upcoming tool in prostate cancer diagnosis.
机译:在前列腺癌诊断和预后,临床医生通常必须采取决定哪些前列腺癌症疑似患者应经过活检,并且前列腺癌症诊断患者应该接受治疗,以克服过度诊断和过度处理。已经开发和商业化了许多基于生物标记的测试,以指导临床医生的决策过程。由于目前可获得各种基于生物标志物的测试,该综述概述了所有商业上可获得的前列腺癌诊断和预后的测试。对于诊断设置,讨论了PHI,4K,MIPS,SelectMDX,Exodx,Proclarix,Charmbmdx,PCA3和PCMT,而对于预后设置,讨论了Prolaris,OnCotypeDX和破译测试。以下是提供了比较生物标志物测试性能的研究的概述。接下来,讨论了使用互补的生物标志物试验与使用多射磁共振成像进行诊断,以诊断前列腺癌的诊断,这是前列腺癌诊断的即将到来的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号